Silexion Submits Pancreatic Cancer Trial App in Israel
Preclinical data for SIL204 reported up to 99.7% cancer cell inhibition across multiple KRAS mutations, and recently completed two-species...
Beacon’s XLRP Gene Therapy Trial Treats Its First Patient
Interim Phase 2 data for laru-zova have shown sustained gains on low-luminance visual acuity and microperimetry, with participants generally...
Arch Biopartners’ Phase II AKI Trial Gets Ethics Approval
Arch Biopartners’ Phase II study in cardiac surgery–associated acute kidney injury (CS-AKI) targets enrollment of 240 on-pump patients, randomizing...
Evolveimmune Initiates Phase 1 Dosing for Solid Tumors
No efficacy or safety data were disclosed. EvolveImmune has dosed the first subject in EIU-104101 (NCT07217171), a first-in-human Phase...
MRT-2359 Shows Compelling Activity in Prostate Cancer Trial
In an interim Phase 1/2 readout in metastatic castration‑resistant prostate cancer (mCRPC), the combination of Monte Rosa’s GSPT1 degrader...
New Hope in Phase 3 Trial for Pancreatic Cancer
Immuneering completed End-of-Phase 2 interactions with the FDA and received EMA scientific advice supporting a global Phase 3 registrational...
InnoCare Announces Important Urticaria Trial Approval in China
InnoCare has received CDE/NMPA clearance to initiate a Phase II/III study of its oral TYK2 inhibitor soficitinib (ICP-332) in...
Acrivon to Announce Clinical Updates for ACR-368, ACR-2316
In an ongoing Phase 1 dose-escalation study, ACR-2316, Acrivon’s WEE1/PKMYT1 inhibitor, showed pharmacodynamic target engagement at the first two...
Tenax Therapeutics Reveals Blinded Sample Size Assessment Data
Tenax’s blinded sample size re-estimation in its Phase 3 LEVEL study indicates the trial retains well over 90% power...
Breakthrough ADAPT Trial Enrollment Complete for Olastrocel
A completed safety review by an independent DSMB reported no significant adverse events, and enrollment has now closed in...